4000 Health Care

NMC Health Plc Monitor

NMC Health Plc Annual Report 2018
CR Monitor Issue: 
2019/0701
Company covered: 
NMC Health Plc
Period End: 
31 December, 2018
Report issued on 01 July 2019 covered the following practice issues:
Pronouncements
Adoption of IFRS 9 Financial Instruments and IFRS 15 Revenue from Contracts with Customers from 1 January 2018.
Pronouncements
Disclosure of the expected impact of IFRS 16 Leases applicable from 1 January 2019.
Change
Recognition of a gain on bargain purchase in the income statement.
Change
The post balance sheet events note includes disclosure of a newly formed strategic partnership.
Change
New disclosures in respect of finance leases acquired during the year.
Change
Extended disclosure within the ‘post employment benefit plans’ note.

GlaxoSmithKline plc Monitor

GlaxoSmithKline plc Annual Report 2018
CR Monitor Issue: 
2019/0618
Company covered: 
GlaxoSmithKline plc
Period End: 
31 December, 2018
Report issued on 19 June 2019 covered the following practice issues:
Pronouncements
Adoption of IFRS 15 Revenue from Contracts with Customers (IFRS 15) and IFRS 9 Financial Instruments (IFRS 9) from 1 January 2018.
Pronouncements
Disclosure in respect of the expected future impact of new accounting standard IFRS 16 Leases.
Change
Disclosure of events after the balance sheet date.
Change
A new section is added to the audit report covering the detection of irregularities including fraud.
Change
The equalisation of Guaranteed Minimum Pensions for men and women results in the recognition of a past service cost.
Change
Disclosure in respect of ‘transactions signed but not yet completed’ within the acquisitions and disposal note.

AstraZeneca Plc Monitor

AstraZeneca Plc Annual Report 2018
CR Monitor Issue: 
2019/0612
Company covered: 
AstraZeneca Plc
Period End: 
31 December, 2018
Report issued on 13 June 2019 covered the following practice issues:
Pronouncements
Adoption of IFRS 9 Financial Instruments, IFRS 15 Revenue from Contracts with Customers and IFRIC 22 Foreign Currency Transactions and Advance Consideration with effect from 1 January 2018.
Pronouncements
Disclosure in respect of future impacts of adoption of IFRIC 23 Uncertainty over Income Tax Treatments and IFRS 16 Leases has been provided.
Pronouncements
Disclosure in respect of Amendments to IFRS 2 Share-based Payments.
Change
Assets held for sale are disclosed separately within the statement of financial position.
Change
The equalisation of Guaranteed Minimum Pensions for men and women results in the recognition of a past service cost.
Change
Disclosures made in respect of post balance sheet events.

Vifor Pharma Ltd. Monitor

Vifor Pharma Ltd. Annual Report 2018
CR Monitor Issue: 
2019/0421
Company covered: 
Vifor Pharma Ltd.
Period End: 
31 December, 2018
Report issued on 26 April 2019 covered the following practice issues:
Pronouncements
Restatement of financial statement due to the adoption of IFRS 15 Revenue from contracts with customers.
Pronouncements
Disclosure in respect of the impact of IFRS 9 Financial instruments.
Pronouncements
Additional disclosure in respect of the expected impact of the new standard IFRS 16 Leases.
Change
Disclosure of a new share-based payment plan.
Change
Additional disclosure in respect of a review of actuarial assumptions.

Chr Hansen Holding A/S Monitor

Chr Hansen Holding A/S Annual Report 2018
CR Monitor Issue: 
2019/0318
Company covered: 
Chr Hansen Holding A/S
Period End: 
31 August, 2018
Report issued on 26 March 2019 covered the following practice issues:
Pronouncements
Additional disclosure in respect of the impact of new accounting standards including IFRS 9 “Financial instruments”, IFRS 15 “Revenue from contracts with customers” and IFRS 16 “leases”.
Pronouncements
Presentation of a reconciliation of movements in liabilities arising from financing activities following adoption of an amendment to IAS 7 "Statement of cash flows".
Change
Added disclosure in respect of alternative performance measures.

UDG Healthcare plc Monitor

UDG Healthcare plc Annual Report 2018
CR Monitor Issue: 
2019/0311
Company covered: 
UDG Healthcare plc
Period End: 
30 September, 2018
Report issued on 19 March 2019 covered the following practice issues:
Change
Exceptional items highlighted within a separate column on the face of the income statement.
Pronouncements
Extended disclosure in respect of the expected future impacts of new accounting standards including IFRS 9 "Financial instruments", IFRS 15 "Revenues from contracts with customers", and IFRS 16 "Leases".
Change
Deferred tax changes recognised following changes to US tax legislation.
Change
Recognition of a significant goodwill impairment.
Pronouncements
Presentation of a reconciliation of movements in liabilities arising from financing activities following adoption of an amendment to IAS 7 "Statement of cash flows".
Change
Detailed disclosure in respect of business disposal.

Smith & Nephew plc Interims Monitor

Interim Financial Report
CR Interim Monitor Issue: 
2019/0112
Period End: 
30 June 2018
Listing Status: 
Europe 350
ICB Industry Classification: 
4533 Health Care Providers
Auditor: 
KPMG
Pronouncements
Adoption of IFRS 9 "Financial instruments"
Pronouncements
Adoption of IFRS 15 "Revenue from contracts with customers"
Pronouncements
Disclosure as to the expected future impacts of IFRS 16 "Leases"
Change
Disclosure of a potential liability linked to a European Commission review into UK Controlled Foreign Company tax rules.

Dechra Pharmaceuticals plc Monitor

Dechra Pharmaceuticals plc Annual Report 2018
CR Monitor Issue: 
2019/0115
Company covered: 
Dechra Pharmaceuticals plc
Period End: 
30 June, 2018
Report issued on 22 January 2019 covered the following practice issues:
Pronouncements
Disclosure in respect of the expected impact of new accounting standards including IFRS 9 "Financial instruments", IFRS 15 "Revenue from contracts with customers” and IFRS 16 “Leases”.
Change
Discussion of key audit matters included in the audit report including identification of a new key audit matter.
Change
Deferred tax changes recognised following changes to US tax legislation.
Change
Change in allocation of goodwill to cash generating units for impairment test purposes.
Change
Disclosure regarding remeasurement of contingent consideration.

Novartis Interims Monitor

Interim Financial Report
CR Interim Monitor Issue: 
2019/0105
Period End: 
30 June 2018
Listing Status: 
Europe 350
ICB Industry Classification: 
4577 Pharmaceuticals
Auditor: 
PricewaterhouseCoopers
Pronouncements
Adoption of IFRS 9 "Financial instruments"
Pronouncements
Adoption of IFRS 15 "Revenue from contracts with customers".
Change
Changes made in segmental reporting following completion of an internal reorganisation.

Genus plc Monitor

Genus plc Annual Report 2018
CR Monitor Issue: 
2018/1119
Company covered: 
Genus plc
Period End: 
30 June, 2018
Report issued on 27 November 2018 covered the following practice issues:
Change
Reclassification in balance sheet as a result of "refining" biological assets accounting policy.
Pronouncements
Extended disclosure in respect of the future impacts of IFRS 15 "Revenue from contracts with customers", IFRS 16 "Leases"and IFRS 9 "Financial instruments.
Change
Revaluation of deferred tax liabilities following reduction in US corporate tax rate.
Change
Amounts linked to post balance sheet event recognised during the year.
Change
Changes made in segmental reporting disclosure.